Please try another search
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
Lota S. Zoth | 63 | 2020 | Independent Director |
Kathleen D. LaPorte | 61 | 2021 | Independent Director |
Steven M. Altschuler Buser | 70 | 2020 | Independent Chairman of the Board |
Rohan Palekar | 57 | 2018 | CEO & Director |
Martin Babler | 59 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review